Pharmaceutical Economics

In this article, Dr. George Korenko and Dr. Tram Nguyen identify dimensions along which, over aggregation and averaging, likely lead to findings of uninjured class members.

In this article, published in Law360, Edgeworth Partner Dr. George Korenko and Principal Consultant Dr. Tram Nguyen discuss three key issues cited in the Court of Appeals opinion and their implications for the economic analysis of predominance in the Lamictal case and in other pay-for-delay litigations.

When pharmaceutical manufacturers develop a new branded drug to take to market, they are granted a period of exclusivity via patent to help recoup the massive costs of research and development. Upon expiration of this patent, generic manufacturers can enter the market with therapeutically equivalent products and compete with the brand.

A panel of distinguished thought leaders, including Edgeworth Principal Tram Nguyen, provide the audience with an in-depth discussion of the trends, developments, and critical issues surrounding pharmaceutical antitrust matters. 

Edgeworth Economics will host the Antitrust Economics Workshop, to be held in advance of the 47th Annual Conference on International Antitrust Law

In this webcast, Dr. George Korenko will join other thought leaders to present on antitrust litigation and regulatory trends, their implications on the life sciences industry, and best practices for compliance. 

Edgeworth Economics debuts The Antitrust Prescription, the firm’s new blog that covers antitrust and other economic issues affecting companies in the pharmaceutical industry.

In the latest article for The Antritrust Prescription, Edgeworth Managing Principal Dr. Ashley Zhou examines recent enforcement concerning the listing of patents in the FDA's Orange Book and potential economic implications of new enforcement efforts.

In this new article for The Antitrust Prescription, our pharmaceutical economics team discusses Amgen’s proposed acquisition of Horizon and the FTC’s broader approach to challenging conduct under Section 5 of the FTC Act. 

In this edition of The Antitrust Prescription, our Pharmaceutical Economics team discusses Merck and Glenmark's  settlements with direct purchasers, end payors, and retailers worth over a combined $600 million. 

In this article, Dr. George Korenko and Dr. Tram Nguyen discuss a brief history of the numerosity standards and the potential implications of recent decisions in pharmaceutical antitrust matters.